Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Rituximab
MabThera
Routinely available
SMC (33/03)
30/09/2020
Indication
CD20 positive diffuse large B-cell non-Hodgkin's lymphoma
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
Solution
Comments
September 2004 - Added to the Formulary as a prescribing note, for Specialist Use only. September 2020 - routinely available in line with local guidance, the paediatric licence extension, and national guidance for adults. Included on the Additional List, for Specialist Use only.